What’s New in Pediatric Acne? Stop Picking and Start Applying Well-Tolerated Retinoids!
163311633116331
Linda Stein Gold, Director of Dermatology Clinical Research at Henry Ford Health System, lead us through “Acne across the ages” at the 17th Annual Women’s and Pediatric Dermatology Seminar. She busted through several acne myths, which are easily debunked with new acne medications:
Clascoterone 1% cream: it reduces sebum production in the skin! Similar to spironolactone, it is an anti-andr …
Linda Stein Gold, Director of Dermatology Clinical Research at Henry Ford Health System, lead us through “Acne across the ages” at the 17th Annual Women’s and Pediatric Dermatology Seminar. She busted through several acne myths, which are easily debunked with new acne medications:
Clascoterone 1% cream: it reduces sebum production in the skin! Similar to spironolactone, it is an anti-andr … 
The medication that the FDA recently approved for the treatment of this condition inhibits the same enzymes as which of the following?
A. Ruxolitinib
B. Abrocitinib
C. Apremilast
D. Adalimumab
E. Tofacitinib
To find out the correct answer and read the explanation, click here.
Brought to you by our brand partner Derm In-Review. A product of SanovaWorks.
… 
Everyday Health recently posted an article about the benefits of combined dermatology and rheumatology clinics in the treatment of psoriatic arthritis. Does research show a patient care benefit? What are ways dermatology and rheumatology providers can work better together outside of a combined clinic model?
For expert advice, I reached out to Brad Glick, DO, MPH, clinical assistant professor … 
What sports would be okay for this 14 year old to participate in?
A. Swimming
B. Boxing
C. Football
D. Soccer
E. Hockey
To find out the correct answer and read the explanation, click here.
Brought to you by our brand partner Derm In-Review. A product of SanovaWorks.
… 
Atopic dermatitis is a common, chronic, life-altering disease. With its visibility and debilitating pruritus, atopic dermatitis significantly impacts our patients’ quality of life. For those with resistant and extensive disease, we are happy to have numerous new systemic agents at our disposal, one being tralokinumab, an IL-13 antagonist. We continue our series, Therapeutic Cheat Sheet, with a c … 